🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Day 1 of PSMA & Beyond Conference and Beyond Conference Great panel and Dr. Hoffman talks “virtual biopsies”

Michael Hofman presents at 2025 PSMA & Beyond Conference UCLA UC San Francisco Prostate Cancer Foundation ... Impressive attendance! Thanks to organisers: Thomas Hope Jeremie Calais Johannes Czernin UroToday.com Don't miss our next webinar: Link.prostic.org/webinar

#PRIMARY Score and where it plays a role. Michael Hofman Peter Mac Cancer Centre. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3XEDpg5 Prostate Cancer Foundation PSMA & Beyond Conference #PSMAandBeyond2025

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers ProsTIC PCF Science

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

Getting ready for ASCO #ASCO25? ✈️🔬 There’s lots of theranostics … including a dedicated session for prostate cancer. Don’t miss these! 👀

Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma

Don't miss the first-in-human VIOLET study being presented #ASCO25 ASCO Monday June 2 3:00 PM New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy (awesome research being presented in this session - don't miss the other talks) In press The Lancet Oncology

Great to hear the patient perspective at ASCO #ASCO25 David Matheson ... His initial thought was "cut out all out" but with time to think he opted for radiotherapy...

ANZUP #EVOLUTION trial live at ASCO #GU25 ¹⁷⁷Lu-PSMA-617 + ipilimumab (n=67) + nivolumab vs. ¹⁷⁷Lu-PSMA-617 (n=33) ■ rPFS favouring ¹⁷⁷Lu immunotherapy: HR 0.53 (95% CI 0.32-0.90) ■ PSA-50 RR 75% vs. 67% ■ Grade 3-4 AEs 76% vs. 29% A/Prof. Shahneen Sandhu

Congrats @ANZUPTrials #TheraP study presented #ASCO25 by Dr Aslı Munzur. Thanks to Prostate Cancer Foundation BC Cancer Foundation Terry Fox Foundation #CanadianCancerSociety Peter Mac Cancer Centre ProsTIC Vancouver Prostate Centre VCH Research Institute University of British Columbia PCFA Movember Australia ANSTO @adacap_news NHMRC CTC The Distinguished Gentleman's Ride Novartis

Congrats to our @ANZUPTrials #EVOLUTIONtrial for on their oral presentation by A/Prof. Shahneen Sandhu @ASCO25. This Phase 2 #ProstateCancer trial is supported by PCFA and collaborators NHMRC CTC Bristol Myers Squibb Novartis Thanks Study Co-Chair Louise Emmett & Cancer Australia Ian Davis (Bluesky @profiand)

#ASCO25 #EVOLUTION #pcsm

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Congrats ANZUP #ENZAp study oral presentation by Louise Emmett at #ASCSO25. Movember Australia Cancer Australia Astellas Europe #ARTnet St Vincent's Clinic Roy Morgan Novartis MIM Software GenesisCareUK ANSTO NHMRC CTC Ian Davis (Bluesky @profiand)

Very pleased to see #NucMed perspective is included in a panel discussion on the patient-centerd management of high-risk #PSMA PET N1 disease at ASCO 25, Drs Curtiland Deville (RadOnc), Alberto Birganti(SurgOnc), Alicia Morgan(MedOnc) and David Matheson(Patient ad) SNMMI

Packed house at the first Theranostics Symposium by the University of Wisconsin Initiative for Theranostics and Particle Therapy.

#PET is a critical tool for noninvasive imaging of immune activation and #immunotherapy: Approaches to Imaging Immune Activation Using PET jnm.snmjournals.org/content/66/6/8… Thanks to co-authors! SNMMI Fred Hutch Cancer Center UW Medicine UW Radiology

Continuing Education: Approaches to imaging immune activation using PET. ow.ly/vloI50VSPSh #PETscan #NuclearMedicine #MolecularImaging Amir Iravani Ashwin Singh Parihar, MBBS, MD